**THE SOLUTION PHYSICIANS TRUST AND PATIENTS COUNT ON**

Long-term clinical trial data

U.S. IDE Clinical Trial 5-year data
63 patients* from primary enrollment

<table>
<thead>
<tr>
<th>Metric</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patency — External iliac artery</td>
<td>100%</td>
</tr>
<tr>
<td>Patency — Internal iliac artery</td>
<td>95.1%</td>
</tr>
<tr>
<td>Buttock claudication†</td>
<td>0%</td>
</tr>
<tr>
<td>New onset erectile dysfunction</td>
<td>0%</td>
</tr>
<tr>
<td>Type I/III endoleaks Migrations</td>
<td>ZERO</td>
</tr>
<tr>
<td>Freedom from CIAA† enlargement (&gt; 5 mm)</td>
<td>98.3%</td>
</tr>
<tr>
<td>Freedom from IBE-related reintervention</td>
<td>95.2%</td>
</tr>
</tbody>
</table>

Core Lab reported assessment for patency, endoleak, migration and CIAA enlargement. Denominator is number of subjects evaluated for primary effectiveness endpoint result with an evaluable result.

* Sixty-three subjects with device implanted in initial cohort. Thirty-six patients have completed 5-year follow-up.

† On the side treated with the IBE.

Together, improving life
THE SVS CLINICAL PRACTICE GUIDELINES FOR ABDOMINAL AORTIC ANEURYSM¹ (AAA) INCLUDE RECOMMENDATIONS PERTAINING TO HYPOGASTRIC PRESERVATION DURING EVAR TREATMENT.

These recommendations include:

Preservation of flow to at least one internal iliac artery

Using a Food and Drug Administration (FDA) approved branch endograft in anatomically suitable patients to maintain perfusion to at least one internal iliac artery.

1 (Strong)  A (High)

PRESERVE FLOW. ADVANCE CARE.

- **Preservation matters:** Recommended treatment¹² to sustain quality of life
- **Advances repair:** All-In-One System with proven outcomes
- **Performs as promised:** High patency³, conformability and durability
- **Complete confidence:** More than 20 years of aortic device experience

Learn more at goremedical.com/IBE

Cover image: 5-year follow-up; first clinical use. Image courtesy of Brian Peterson, MD., St. Anthony’s Medical Center; St. Louis, Missouri.

Additional clinical trial data available in Instructions for Use. Additional clinical study information available.³


Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available.³

Products listed may not be available in all markets.

GORE, Together, improving life, EXCLUDER and designs are trademarks of W. L. Gore & Associates.

© 2021 W. L. Gore & Associates, Inc. 21263094-EN OCTOBER 2021